News - Nephrology and Hepatology, Asia-Pacific


Popular Filters

Cytori licenses Asia-Pacific cardiovascular, renal and diabetes markets to Lorem Vascular for up to $531 million


San Diego, USA-based Cytori Therapeutics and China-headquartered Lorem Vascular have entered a partnership…

Asia-PacificBiotechnologyCardio-vascularCytori TherapeuticsDiabetesLicensingLorem VascularMergers & AcquisitionsNephrology and Hepatology

Otsuka's Samsca gains additional indication in Japan


Japanese drugmaker Otsuka (TYO: 4768) says that its vasopressin V2 receptor antagonist Samsca (tolvaptan)…

Asia-PacificNephrology and HepatologyOtsukaPharmaceuticalRegulationSamscatolvaptan

AstraZeneca to fork out $815 million for rights to anemia drug candidate


In yet another move to boost its R&D pipeline, Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered…

Asia-PacificASP1517Astellas PharmaAstraZenecaBiotechnologyFG-4592FibroGenLicensingNephrology and HepatologyNorth AmericaPharmaceuticalResearch

Japanese filings for Shionogi's metreleptin and Otsuka's tolvaptin


Japanese drugmaker Shionogi (TYO: 4507) said last week that it has filed a New Drug Application with…

Asia-PacificmetreleptinNephrology and HepatologyOtsukaPharmaceuticalRare diseasesRegulationSamscaShionogitolvaptin

Astellas debuts Kiklin capsules, for hyperphosphatemia, in Japan


Japanese drug major Astellas Pharma (TYO: 4503) yesterday launched Kiklin capsules 250mg (bixalomar)…

Asia-PacificAstellas PharmaKiklinMarkets & MarketingNephrology and HepatologyPharmaceuticalSanwa Kagaku

Erythropoietin market in Japan to reach $1.54 billion by 2015


The erythropoietin market in Japan is forecast to reach $1.54 billion by 2015 by analysts at TechNavio.…

Asia-PacificBiotechnologyGenericsMarkets & MarketingNephrology and HepatologyPatents

Astellas and Sanwa to co-promote kidney disease drugs in Japan


Japanese drug major Astellas Pharma (TYO: 4503) yesterday revealed that it has linked up with fellow…

ArgamateAsia-PacificAstellas PharmabixalomerMarkets & MarketingNephrology and HepatologyPharmaceuticalSanwa Kagaku

Takeda to drop peginesatide commercialization in Japan


Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) has decided not to commercialize peginesatide…

AffymaxAsia-PacificLicensingNephrology and HepatologypeginesatidePharmaceuticalTakeda Pharmaceuticals

Back to top